The largest community of pharma leaders

Infinity BiologiX Expands Executive Team as Company Continues to Grow and Scale its Commercial Presence and Scientific Innovation

PISCATAWAY, N.J.–()–Today, Infinity BiologiX (IBX), a leading next-generation central laboratory providing sample collection and processing, storage, analytical services, and scientific and technical support, announced two key new hires as part of its executive team. The expanded executive team now includes Craig Eslinger, Vice President of Commercial Affairs, and Mary Storella, Vice President and General Counsel.

In his role as Vice President of Commercial Affairs, Eslinger will oversee the company’s commercial presence as an independent entity following IBX’s spin-off from Rutgers University in August. He will also be charged with building a world-class commercial team as the company expands into new markets. Eslinger comes to IBX with more than 30 years of experience in the pharmaceutical, biotech, medical device, public health, and contract research industries and is also scientifically trained in biochemistry and cyto/histopathology. Most recently he served as Vice President of Commercial Strategy at ICON and has worked for other industry-leading organizations including PPD, and SpaceLabs Medical.

Eslinger commented, “With this role at IBX I have the unique opportunity to build something for a newly launched company which also has a rich history of experience in biobanking, bioprocessing, and analytics.” He continued, “Throughout its 21-year history the company has made a tremendous impact on bringing new products to market and helping healthcare providers use those medicines to effectively treat patients. I’m thrilled to now broaden that impact by expanding our commercial presence to new markets and I look forward to working with this talented executive team in making IBX an industry leader.”

As Vice President and General Counsel, Storella joins IBX with over 20 years of legal and business development experience in the healthcare industry. Most recently, she served as Vice President, Senior Counsel of Corporate Transactions at Celgene Corporation, where she was lead counsel on key strategic transactions. Prior to joining Celgene, Storella served on both the business development and legal teams at Merck & Co., Inc. as Executive Director, Business Development and Director, Corporate Transactions. She will play a pivotal role in establishing legal processes and best practices that support the company’s rapid innovation and fast-paced business model.

I am excited and honored to join IBX at such a pivotal time in the growth of the company and at a time when the company is making such an impact in so many lives,” commented Storella. “I look forward to working with IBX’s management team to build the legal framework necessary to support IBX as an independent company and to reach IBX’s future strategic goals.”

Robin Grimwood, IBX President and COO commented, “IBX is pleased to be bringing on these seasoned professionals who will help lead the company during this important stage of strategic and aggressive growth. Craig’s relationships across the industry and experience building teams are essential as we look for ways to expand our reach and grow our commercial organization quickly and at the highest quality possible.” He continued, “Mary’s unique combination of deep legal experience with a strong business development knowledge, with roles across pharmaceutical and life sciences, will be invaluable for IBX during this time of growth.”

Eslinger and Storella join the current IBX executive team which, in addition to Grimwood, includes Dr. Andrew Brooks, Chief Executive and Scientific Officer, and Russell Hager, Executive VP and Strategic Operations.

About Infinity BiologiX

Infinity BiologiX (IBX) is a market-disrupting next-generation central laboratory. It collaborates with, and provides services to researchers and organizations in both the public and private sectors, including sample collection and processing, storage and analytical services, and scientific and technical support in both the research and clinical arenas. The company was previously RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020.

For more information, visit


Recent Articles